ArticleRNA biology2021
crRNA complementarity shifts endogenous CRISPR-Cas systems between transcriptional repression and DNA defense.
Article in RNA biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- MtvS1 and MtvS2 Interact with RNA polymerase to regulate the Francisella type V-A CRISPR-Cas system.Nature communications · 2026Article
- CRISPR-enabled functional genomics for bolstering plant tolerance to abiotic and biotic stress; a comprehensive review.Functional & integrative genomics · 2026Review
- A CRISPR array orchestrates virulence and host response inMicrobiology spectrum · 2026Article
- Widespread CRISPR-derived RNA regulatory elements in CRISPR-Cas systems.Nucleic acids research · 2023Article
- Widespread CRISPR repeat-like RNA regulatory elements in CRISPR-Cas systems.bioRxiv : the preprint server for biology · 2023Article
- CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses.Molecular biomedicine · 2022Review
- Evolutionary plasticity and functional versatility of CRISPR systems.PLoS biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
CRISPR-Cas systems are prokaryotic adaptive immune systems that recognize and cleave nucleic acid targets using small RNAs called CRISPR RNAs (crRNAs) to guide Cas protein(s). There is increasing evidence for the broader endogenous roles of these systems. The CRISPR-Cas9 system of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.